论文部分内容阅读
选择BCR/ABL cDNA 0.3kb的接合区序列,标记Biotin-14-dCTP,与慢性粒细胞白血病(CML)患者的细胞涂片原位杂交,链霉亲和素-碱性磷酸酶显色系统检测,建立了原位杂交检测BCR/ABL基因表达的方法。对3例非CML的血液病患者(对照组)、18例CML初诊和8例治疗后的CML患者骨髓进行检测。CML初诊患者17/18为阳性,1例阴性反应来自Ph染色体阴性型患者,CML治疗后患者BCR/ABL mRNA表达3/8为阳性,5/8为阴性。结合各例骨髓增生活跃程度,表明BCR/ABL基因表达水平可以反映治疗效果。
BCR/ABL cDNA 0.3kb ligated sequence was selected and labeled with Biotin-14-dCTP. In situ hybridization with cytoplasmic smears in patients with chronic myelogenous leukemia (CML) and streptavidin-alkaline phosphatase staining system A method for the detection of BCR/ABL gene expression by in situ hybridization was established. The bone marrow was examined in 3 patients with non-CML hematologic disease (control group), 18 patients with CML initial diagnosis, and 8 patients with CML after treatment. The newly diagnosed patients with CML were positive in 17/18, and one negative reaction was from Ph chromosome-negative patients. After CML treatment, the expression of BCR/ABL mRNA was positive in 3/8 and negative in 5/8. Combined with each case of myeloproliferative activity, the BCR/ABL gene expression level can reflect the therapeutic effect.